BDTX Black Diamond Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1701541 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-100.0%
TTM net income YoY-305.0%
TTM EPS YoY-305.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-41.1%
ROA-32.3%
ROIC (approx.)-49.8%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets23.8%
Debt / equity0.00x
Current ratio6.92x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.76x
Accruals ratio-7.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $70.00M | $0 | — | — | — |
| R&D expense | $33.56M | $51.31M | $59.35M | $64.44M | $96.83M |
| SG&A expense | $16.57M | $27.47M | $27.11M | $28.39M | $30.04M |
| Operating income | $12.52M | -$78.78M | -$86.46M | -$92.83M | -$126.87M |
| Interest expense | — | — | — | — | $0 |
| Pretax income | $22.36M | -$69.68M | -$82.64M | -$91.27M | -$125.33M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | $22.37M | -$69.68M | -$82.44M | -$91.17M | -$125.60M |
| EBITDA | $12.85M | -$78.44M | -$86.02M | -$92.32M | -$126.67M |
| EPS (basic) | 0.39 | -1.27 | -1.88 | -2.52 | -3.47 |
| EPS (diluted) | 0.39 | -1.27 | -1.88 | -2.52 | -3.47 |
| Weighted avg. shares (diluted) | 57.56M | 55.03M | 43.95M | 36.33M | 36.19M |
| Balance sheet | |||||
| Cash & equivalents | $20.99M | $37.26M | $57.04M | $35.48M | $67.02M |
| Short-term investments | $107.66M | $62.14M | $75.18M | $88.49M | $143.99M |
| Current assets | $132.44M | $101.18M | $134.03M | $127.71M | $215.70M |
| PP&E, net | $365,000 | $1.39M | $1.73M | $2.59M | $3.04M |
| Total assets | $143.01M | $122.64M | $158.57M | $156.25M | $247.68M |
| Current liabilities | $15.73M | $20.57M | $19.65M | $15.26M | $23.64M |
| Total liabilities | $30.80M | $39.35M | $41.83M | $40.56M | $51.78M |
| Shareholders' equity | $112.21M | $83.28M | $116.74M | $115.69M | $195.90M |
| Shares outstanding | 57.14M | 56.64M | 51.65M | 36.43M | 36.23M |
| Cash flow statement | |||||
| Operating cash flow | $29.61M | -$62.30M | -$66.72M | -$85.08M | -$100.15M |
| Capital expenditure | — | $0 | $33,000 | $192,000 | $2.71M |
| Free cash flow | — | -$62.30M | -$66.75M | -$85.27M | -$102.86M |
| Investing cash flow | -$44.91M | $16.97M | $16.35M | $53.37M | $130.61M |
| Financing cash flow | -$146,000 | $25.55M | $71.93M | $177,000 | $729,000 |
| Depreciation & amortization | $325,000 | $343,000 | $437,000 | $508,000 | $205,000 |
| Stock-based compensation | $6.63M | $10.63M | $9.60M | $12.20M | $14.04M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.